17,261 trials
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With Treatment-emergent (TE) Serious Adverse Events (SAEs) — 5; 2 Participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Overall Response Rate (ORR) in Biomarker Positive AML or HR-MDS Participants Treated With Tamibarotene Monotherapy or in Combination With Azacitidine — 2; 0; 4; 12…
Warm Autoimmune Hemolytic Anemia · Cold Agglutinin Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 5; 5; 7; 6 Participants
Tinnitus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 1 Participants
COVID-19 Infection
Primary: Number and Percentage of Participants With Complications Related to Post COVID-19 Infection — 4; 8; 5; 17 Participants
Inflammatory Bowel Diseases · Clostridium Difficile Infection
Primary: Number of Participants With Clostridium Difficile Recurrence — 4; 1 Participants — p=0.15
Myeloproliferative Disorders
Primary: Number of Patients With Complete Response (CR) or Partial Response (PR) — 3; 3; 14; 23 Participants
Knee Osteoarthritis
Primary: Largest Change From Baseline on Clinical Pain Rating — 24.19; 30.48; 28.55; 26.38 score on a scale — p=.021
Ischemia-Reperfusion Injury · Lung Transplantation
Primary: PaO2/FiO2 Ratio at ICU Admission (Time 0) and 24 Hours — 346.3; 337.9; 320.1; 307.3 ratio of PaO2/FiO2 — p=0.8541
Solid Tumor, Adult
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0; 0; 0 Participants
Spinal Cord Injury
Primary: Muscle Size Change — 47.76; 31.1; 52.4; 36.0 Muscle CSA (cm^2)
COVID-19
Primary: Geometric Mean of Area Under the Curve (AUC) of Antibody Against WA-1 S2-P for Cohort 1 — 2940.97; 26101.97; 14223.28; 2926.70 Arbitrary Unit*1/dilution
Advanced Cutaneous Squamous Cell Carcinoma
Primary: Overall Response Rate (ORR) by Independent Central Review — 50.8; 44.9; 46.4; 61.9 percentage of participants
Prostate Cancer
Primary: Assess the Efficacy of Radium-223 in Terms of Radiological rPFS — 5.53 months
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale